Zalyalov et al. abstract
Citation: Cellular Therapy and Transplantation, Vol. 1, No. 1, 30 May 2008,
doi: 10.3205/ctt2008-05-30-003-en-a
Role of аnti-thymocyte globulin in preventing graft rejection and acute Graft versus Host Disease after allogenic hematopoietic stem cell transplantation
Zalyalov Yy.R., Ganapiev B.A., Potapenko V.G., Mikhailova N.B., Afanasyev B.V.
Summary
Acute GVHD and graft rejection are the main early complications of allo-SCT. In our research, we analyzed a probability of development for main early complications in 109 patients with different oncohematological diseases. We have evaluated results of 112 allo-SCT from related and unrelated donors subjected to myeloablative and nonmyeloablative conditioning regimens, either with or without ATG. Usage of ATG provides effective control over aGVHD, without increasing risk of a relapse of basic disease and reduces the probability of graft rejection to 7%. Consequently, our data on ATG application in allo-HSCT demonstrate its ability to effectively decrease a risk of early complications post-transplant, thus favoring an increase of 4-year overall survival, in comparison to control group without usage of ATG.
Keywords: аntithymocyte globulin, hematopoietic stem cell transplantation, Graft-versus-host disease, graft rejection
Full text
<-- Previous abstract Contents Next abstract -->
<-- Предыдущее резюме Oглавление Cледующее резюме -->
funded by:
